Researchers analyzed the susceptibility profile of a colonizing CRE to forecast its susceptibility when recovered from a clinical specimen. Ultimately, the researchers observed an overall agreement of 88.7 percent for the combinations of 11 antibiotics with 53 pairs of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae.
That said, there were also considerable errors observed for aminoglycoside agents and colistin, meaning the predictability of the susceptibility profile for these clinical isolates is limited.
“We recommend caution when prior surveillance results are used to guide therapy,” the authors concluded.
More articles on CRE:
Could hospital waste hosting superbugs spread the bacteria to the public?
Study examines risk of CRE colonization becoming an infection: 3 findings
CDC report reveals CRE is on the rise: 5 things to know
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
